NeXagen other research news

The Boulder, Colo., company published data on its Selex technology, which generates libraries of RNA or DNA oligomers, showing that an RNA molecule so generated can bind the asthma therapeutic theophylline with high affinity and specificity.

The dissociation constant for theophylline was 0.1 micromolar, as reported in Science, and this was 10,000-fold more potent than its binding to the closely related molecule, caffeine. The affinity for theophylline is 10 times higher than that of antibodies currently available for the drug, the company noted. ...